Skandal! - 500 Beiträge pro Seite

[MH120480]

Seit Dezember wurden zwischen Celera Genomics und dem Human Genome Project (staatlich gefördert), Verhandlungen über eine Kooperaton geführt!
Man konnte sich in einem Punkt nun gar nicht enig werden, über die kommerzielle Nutzung der Forschungsergebnisse.
Die Verhandlungen scheiterten daran, das Wellcome Trust (Mitgründer vom Human Genome Project), einen vertraulichen Brief von Genome an Celera, an die Presse weiterleitete....

Dann gestern diese Nachricht:

Biotech Drops After Clinton-Blair Comment
NEW YORK (Reuters) - The sell-off of U.S. biotechnology firms accelerated on Tuesday after the leaders of the United States and Britain said scientists worldwide should have free access to research on the mapping of human genes.
The Nasdaq biotech index (^IXB - news), which includes more than 200 U.S. and European companies, was down 8.25 percent in afternoon trade, after falling as much as 14 percent.

The drop came after President Clinton and British Prime Minister Tony Blair called research into the human genetic blueprint ``one of the most significant scientific projects of all time`` and proposed that to fully realize its potential the data should be freely available.

That sent shares of genomics companies -- which are making money or hope to profit from that information -- into further decline, extending a week-long downturn in biotechnology shares, including genomics.

But the Nasdaq biotech stocks remain up nearly 37 percent from the beginning of the year, riding high from a sustained bull run that began last year on the promise that gene mapping and its off-shoots could revolutionize medicine and reap rewards for early investors.

``The catalysts du jour for the downtrend are the comments made by Clinton and Blair,`` said Richard Van Den Broek, an analyst with Chase Hambrecht & Quist.

Analyst Eric Ende of Lehman Brothers said several issues were hurting the market, including disappointing trial results for Chiron Corp`s (NasdaqNM:CHIR - news) FGF-2 drug for treating coronary artery disease as well as Clinton`s support of putting genomic data into the public domain.

``The news on Chiron was pretty negative and some (investors) are thinking `Hey, maybe this genomics stuff isn`t as sure fire as originally thought,``` said Ende.

Ende said the recent spate of news helped accelerate the decline in the biotech sector, which ``was already in a profit-taking mode.``

The politicians` call came a week after U.S. company Celera Genomics (NYSE:CRA - news), racing to become the first firm to sequence all the genes in the human body, said it was concerned that if it shared information with publicly funded research centers its data would be used by rivals.

Celera is one of a number of private companies that plan to patent or otherwise license their information on human genes for profit.

It has been in talks to enter into partnership with the publicly funded team of international researchers working on the Human Genome Project, but the talks appeared to fall apart last week over its demands to retain exclusive commercial rights of distribution of any merged products.

Van Den Broek called the leaders` statements political positioning ahead of some sort of public and private sector agreement and said he still believed in the fundamental value of a few leading genomics companies.

``(Today`s drop is) an important and valuable wake-up call that this is a highly speculative area,`` Van Den Broek said.

Shares of biotech companies hurt on Tuesday included Abgenix Inc.(NasdaqNM:ABGX - news), down 48 3/8 at 270 1/8, Onyx Pharmaceuticals Inc.(NasdaqNM:ONXX - news), down 6 1/8 at 21 3/8, and Lynx Therapeutics Inc. (NasdaqNM:LYNX - news) down 14 at 52.

[bEine Rache, an Celera?[/b]

Mfg MH

[MH120480]

Eine Rache an Celera?

So sollte das natürlich aussehen...

Man sollte noch anmerken, das Human Genome schlechter vorankommt als Celera...

Mfg MH

[bioscope]

Hallo MH,

ich glaube, dies ist vor allem Schuld von PE/celera. Jahrelang hat man sich aus dem Fenster gelehnt und eben nur das Thema "Entschluesselung und Patentierung von Genen" promoted. Jeder Anleger bringt PE/Celera damit in Verbindung. PE/Celera ist weiter als jeder andere Wettbewerber, hat v.a. das schnellste Verfahren entwickelt. Aber das typisch grosskotzige amerikanische Management haette etwas dezenter agieren sollen, denn es gilt, wer hohe Erwartungen weckt, muss diese nicht 100 sondern 150%tig erfuellen. Ausserdem ist man anderen zu stark auf die Fuesse getreten. Da sind diese Reaktionen nur verstaendlich. PE Celera waere uebrigens auf diesem Niveau ein interessanter buy, aber mich hat die aggressive PR erstmal abgeschreckt.

Wie siehts uebrigens mit Deiner "Biotech-Start-up" Kolumne aus? Kein Bock mehr?

Ich sage nur GPC! Spatestens dann sehen wir uns wieder.

Gruss bioscope

[MH120480]

An dem BioTech-Research bin ich noch dran, ob das hier allerdings jemals veröffentlicht wird ist fraglich...hierzu folgender Thread:

http://www.wallstreetonline.de/community/board/ws/threads/95…

Soweit zu hören war, sind die jetzt sogar wieder am verhandeln...das Human Genome Projekt ist auf Celera in einem offenen Brief zugegangen...man sei zu konstruktiven Gesprächen bereit...

Naja ich halt mich von den Dingern fern...Guilfor is momentan wieder interessant! Nach dem Rückschlag, bieten sich viele gute Einstiegsmöglichkeiten...doch sollte man sich beeilen, denn die Erholung ist im vollen Gange!

Die größten Unstimmigkeiten gab es bei der Frage der kommerziellen Nutzung! Human genome wollte das ganze nach 6-12 Monaten freigegeben, Celera wollte die Exclusiv-Rechte bis 2005!

Mfg MH

[bioscope]

Da klicke ich nichtsahnend auf Deinen thread und schwupps lese ich Deinen Abschiedsbrief. Viel Glueck bei was auch immer. Wir sollten mal rausfinden wann GPC den Boersengang plant. Ich mach mich auch mal schlau.

[Dritte Million]

The day after the Clinton/Blair statement on making genomic information "freely available," stocks in the biotech sector continued to be highly volatile, and recoveries from Tuesday`s bloodbath were few and far between.

With 48 hours now passed since the statement, investors are able to understand its context more richly. And its not pretty. Lori Andrews, America`s foremost legal authority on genetics, has written a must-read posting on the Think Tank board yesterday, revealing the sinister political motivations behind the Clinton/Blair statement.

Andrews writes, The political story behind the Blair/Clinton statement on genes is an interesting one, and represents a desperate grab for power by the NIH`s Human Genome Research Institute.

Andrews points out that Celera Genomics has disrupted the unholy alliance between government and business that has been at the heart of the government sponsored Human Genome Project. The essence is that government-funded HGP scientists have been able to file for patents on genes discovered in the course of their government-funded work -- and keep the patents for themselves. Celera threatens that game by making raw sequence data on the human genome available to thousands of universities and businesses cheaply and rapidly -- so the government-funded insiders won`t be able to grab the patentable goodies first.

As Andrews puts it, When Celera announced that it could do the effort more quickly than the government-funded project, NIH researchers panicked. Francis Collins, head of the genome project at NIH, had managed to convince the NIH and Congress to go beyond the temporary project funding of 15 years to create a permanent institute at NIH -- the Human Genome Research Institute and endow it with tons of funding. When Celera made its move, members of Congress began to wonder why it was necessary to use private funds to underwrite a project that might (dare I say it) be done more efficiently by private business. So, a massive public relations campaign began to make the NIH researchers appear to be the guys in the white hats. This included testimony in Congressional hearings where Francis Collins said that NIH would discourage patenting. He implied in that setting and elsewhere that he disapproved of Celera`s patenting genes. Collins did not reveal in his testimony that he himself had patented genes. In fact, a new tech transfer law passed a decade ago allows government researchers to patent inventions (including genes) that were developed with public funds -- government researchers can earn an extra $150,000 per year for their gene patent. The new law also allows them to enter into joint ventures with companies. To me, NIH`s behavior is worse than that of the biotech companies they are criticizing since researchers can privately benefit from work done with public funds.

We`ve always admired Celera for its bold strategy to privatize research that was once thought to be the exclusive province of government (and government insiders!). We`re now seeing a very public battle in which Celera will have to defend the property rights underlying its business model. It will be a volatile time for Celera. Friends of freedom and innovation should pray that they will win.

[tgfn]

hallo

ist ja hochinteressant. gerade andersrum als ich immer dachte. by the way, was ist den das think tank board?

gruß tgfn